Replimune cut to Underweight at J.P. Morgan on further headline risk
Source: SeekingAlpha
2025-09-19 11:17:20 ET
More on Replimune Group
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune down amid uncertainty over accelerated approval
- Replimune gains as FDA to discuss path for rejected skin cancer drug
- Seeking Alpha’s Quant Rating on Replimune Group
Read the full article on Seeking Alpha
For further details see:
Replimune cut to Underweight at J.P. Morgan on further headline risk
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
7.97% G/L:
$5.02 Last:
609,269 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
